CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation

NYSE:CRL • US1598641074

174.46 USD
-6.86 (-3.78%)
At close: Mar 6, 2026
174.46 USD
0 (0%)
After Hours: 3/6/2026, 8:09:47 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall CRL gets a fundamental rating of 4 out of 10. We evaluated CRL against 57 industry peers in the Life Sciences Tools & Services industry. CRL has only an average score on both its financial health and profitability. CRL has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. CRL Profitability Analysis

1.1 Basic Checks

  • CRL had positive earnings in the past year.
  • In the past year CRL had a positive cash flow from operations.
  • CRL had positive earnings in 4 of the past 5 years.
  • CRL had a positive operating cash flow in each of the past 5 years.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • CRL has a better Return On Assets (-2.02%) than 61.40% of its industry peers.
  • With a decent Return On Equity value of -4.56%, CRL is doing good in the industry, outperforming 61.40% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 6.60%, CRL is doing good in the industry, outperforming 77.19% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for CRL is below the industry average of 11.61%.
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROIC 6.6%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • CRL has a Operating Margin of 12.51%. This is in the better half of the industry: CRL outperforms 73.68% of its industry peers.
  • CRL's Operating Margin has declined in the last couple of years.
  • The Gross Margin of CRL (34.98%) is worse than 61.40% of its industry peers.
  • In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
Industry RankSector Rank
OM 12.51%
PM (TTM) N/A
GM 34.98%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CRL Health Analysis

2.1 Basic Checks

  • CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for CRL has been reduced compared to 1 year ago.
  • Compared to 5 years ago, CRL has less shares outstanding
  • Compared to 1 year ago, CRL has a worse debt to assets ratio.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 2.47 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • CRL's Altman-Z score of 2.47 is fine compared to the rest of the industry. CRL outperforms 66.67% of its industry peers.
  • CRL has a debt to FCF ratio of 4.13. This is a neutral value as CRL would need 4.13 years to pay back of all of its debts.
  • CRL has a Debt to FCF ratio of 4.13. This is in the better half of the industry: CRL outperforms 73.68% of its industry peers.
  • A Debt/Equity ratio of 0.68 indicates that CRL is somewhat dependend on debt financing.
  • CRL's Debt to Equity ratio of 0.68 is on the low side compared to the rest of the industry. CRL is outperformed by 71.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Altman-Z 2.47
ROIC/WACC0.63
WACC10.53%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • CRL has a Current Ratio of 1.29. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.29, CRL is doing worse than 77.19% of the companies in the same industry.
  • CRL has a Quick Ratio of 1.02. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • CRL's Quick ratio of 1.02 is on the low side compared to the rest of the industry. CRL is outperformed by 77.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.02
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CRL Growth Analysis

3.1 Past

  • CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.39%.
  • Measured over the past 5 years, CRL shows a small growth in Earnings Per Share. The EPS has been growing by 4.78% on average per year.
  • The Revenue has decreased by -0.85% in the past year.
  • CRL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.55% yearly.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%

3.2 Future

  • Based on estimates for the next years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.70% on average per year.
  • The Revenue is expected to grow by 3.26% on average over the next years.
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

6

4. CRL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 16.97, which indicates a correct valuation of CRL.
  • 87.72% of the companies in the same industry are more expensive than CRL, based on the Price/Earnings ratio.
  • CRL is valuated rather cheaply when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 15.88, CRL is valued correctly.
  • 89.47% of the companies in the same industry are more expensive than CRL, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 24.57. CRL is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 16.97
Fwd PE 15.88
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaply inside the industry as 92.98% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, CRL is valued cheaper than 87.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.56
EV/EBITDA 11.98
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.47
PEG (5Y)3.55
EPS Next 2Y8.98%
EPS Next 3Y8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRL Dividend Analysis

5.1 Amount

  • No dividends for CRL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRL Fundamentals: All Metrics, Ratios and Statistics

CHARLES RIVER LABORATORIES

NYSE:CRL (3/6/2026, 8:09:47 PM)

After market: 174.46 0 (0%)

174.46

-6.86 (-3.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18
Earnings (Next)05-05
Inst Owners110.03%
Inst Owner Change3.99%
Ins Owners0.94%
Ins Owner Change4.42%
Market Cap8.59B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.28 (18.24%)
Short Float %6.07%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)-1.14%
PT rev (3m)6.95%
EPS NQ rev (1m)-20.71%
EPS NQ rev (3m)-21.1%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)1.02%
Revenue NQ rev (1m)-0.99%
Revenue NQ rev (3m)-1.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
Industry RankSector Rank
PE 16.97
Fwd PE 15.88
P/S 2.14
P/FCF 16.56
P/OCF 11.64
P/B 2.71
P/tB 142.21
EV/EBITDA 11.98
EPS(TTM)10.28
EY5.89%
EPS(NY)10.99
Fwd EY6.3%
FCF(TTM)10.53
FCFY6.04%
OCF(TTM)14.99
OCFY8.59%
SpS81.58
BVpS64.3
TBVpS1.23
PEG (NY)2.47
PEG (5Y)3.55
Graham Number121.95
Profitability
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROCE 8.35%
ROIC 6.6%
ROICexc 6.84%
ROICexgc 14.71%
OM 12.51%
PM (TTM) N/A
GM 34.98%
FCFM 12.91%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Debt/EBITDA 2.36
Cap/Depr 54.34%
Cap/Sales 5.46%
Interest Coverage 4.94
Cash Conversion 81.47%
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.02
Altman-Z 2.47
F-Score5
WACC10.53%
ROIC/WACC0.63
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year26.23%
EBIT Next 3Y12.9%
EBIT Next 5Y7.36%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%

CHARLES RIVER LABORATORIES / CRL FAQ

What is the fundamental rating for CRL stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRL.


What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?

ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.


How profitable is CHARLES RIVER LABORATORIES (CRL) stock?

CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for CRL stock?

The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 6.87% in the next year.